EA201690766A1 - Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний - Google Patents

Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний

Info

Publication number
EA201690766A1
EA201690766A1 EA201690766A EA201690766A EA201690766A1 EA 201690766 A1 EA201690766 A1 EA 201690766A1 EA 201690766 A EA201690766 A EA 201690766A EA 201690766 A EA201690766 A EA 201690766A EA 201690766 A1 EA201690766 A1 EA 201690766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
soluble
diseases
bulse
immune
Prior art date
Application number
EA201690766A
Other languages
English (en)
Other versions
EA034176B1 (ru
Inventor
Ральф Людвиг
Петер Сондерман
Доминик Тер Мер
Original Assignee
Зуппремоль Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зуппремоль Гмбх filed Critical Зуппремоль Гмбх
Publication of EA201690766A1 publication Critical patent/EA201690766A1/ru
Publication of EA034176B1 publication Critical patent/EA034176B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение, в целом, относится к области биотехнологии и медицины. Оно предлагает средство, фармацевтическую композицию и набор для лечения аутоиммунных буллезных заболеваний (AMDB). Более конкретно, изобретение относится к применению растворимого Fc-гамма рецептора для лечения AMDB, а также к фармацевтической композиции и набору, содержащим указанный рецептор. Оно дополнительно предусматривает способ лечения AMDB.
EA201690766A 2013-10-16 2013-10-16 РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ EA034176B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/071599 WO2015055240A1 (en) 2013-10-16 2013-10-16 Soluble fc gamma receptor for treatment of autoimmune bullous diseases

Publications (2)

Publication Number Publication Date
EA201690766A1 true EA201690766A1 (ru) 2016-07-29
EA034176B1 EA034176B1 (ru) 2020-01-14

Family

ID=49596237

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690766A EA034176B1 (ru) 2013-10-16 2013-10-16 РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ

Country Status (13)

Country Link
US (1) US9981009B2 (ru)
EP (1) EP3057606B1 (ru)
JP (1) JP2016539920A (ru)
KR (1) KR102138219B1 (ru)
CN (1) CN105873600B (ru)
AU (1) AU2013403046B2 (ru)
BR (1) BR112016008288A2 (ru)
CA (1) CA2927263C (ru)
EA (1) EA034176B1 (ru)
IL (1) IL245116B (ru)
MX (1) MX371137B (ru)
NZ (1) NZ719745A (ru)
WO (1) WO2015055240A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
CA2927263C (en) 2013-10-16 2022-12-13 Suppremol Gmbh Soluble fc gamma receptor for treatment of autoimmune bullous diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
US10028998B2 (en) * 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
CA2927263C (en) 2013-10-16 2022-12-13 Suppremol Gmbh Soluble fc gamma receptor for treatment of autoimmune bullous diseases

Also Published As

Publication number Publication date
KR20160061430A (ko) 2016-05-31
JP2016539920A (ja) 2016-12-22
AU2013403046A1 (en) 2016-05-26
EP3057606B1 (en) 2020-03-11
IL245116A0 (en) 2016-06-30
WO2015055240A1 (en) 2015-04-23
KR102138219B1 (ko) 2020-07-28
US9981009B2 (en) 2018-05-29
AU2013403046B2 (en) 2020-02-06
CN105873600A (zh) 2016-08-17
CN105873600B (zh) 2019-11-05
CA2927263C (en) 2022-12-13
NZ719745A (en) 2018-10-26
EA034176B1 (ru) 2020-01-14
BR112016008288A2 (pt) 2017-09-26
CA2927263A1 (en) 2015-04-23
MX371137B (es) 2020-01-17
IL245116B (en) 2019-09-26
MX2016004799A (es) 2016-07-26
EP3057606A1 (en) 2016-08-24
US20160235814A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
PH12018501248A1 (en) Biprazolyl derivatives useful for the treatment of autoimmune diseases
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CR20130624A (es) Proteínas de unión a antígeno
EA201590058A1 (ru) Аналоги глюкагона
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201690371A1 (ru) Пиридазиноновые соединения и их применение
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201691881A1 (ru) Новые соединения
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM